.After raising $170 million back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the public market.The Eli Lilly-partnered biotech intend to list on the Nasdaq under the symbolic representation "BIOA," depending on to records filed with the Securities and Exchange Percentage. The firm has not openly shared an assumed financial amount for the offering.The clinical-stage company boasts lead prospect azelaprag, an orally supplied little molecule slated to enter phase 2 screening in combo with semaglutide-- marketed by Novo Nordisk under brand Wegovy for weight loss-- in the 1st half of next year. Semaglutide is actually likewise offered as Ozempic as well as Rybelsus by Novo for diabetes mellitus.
Apelin receptor agonist azelaprag is designed to blend effectively along with GLP-1 drugs, enhancing weight loss while maintaining muscle mass. The investigational drug was actually located to become well-tolerated among 265 individuals around eight phase 1 tests, depending on to BioAge.Earlier, BioAge garnered the assistance of Lilly to manage a test mixing azelaprag along with the Big Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and Zepbound for fat loss. The partners are currently carrying out a period 2 trial of azelaprag and also tirzepatide, along with topline end results anticipated in the 3rd quarter of 2025.The biotech is actually also organizing an insulin level of sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the first one-half of following year to assist potential indicator development. On top of that, the provider considers to talk to the FDA for approval in the 2nd half of 2025 to introduce human screening for an NLRP3 prevention targeting metabolic diseases and also neuroinflammation.BioAge's anticipated transfer to everyone market adheres to a small uptick in planned biotech IPOs from Bicara Therapies as well as Zenas Biopharma. Zooming out, the current IPO yard is actually a "combined picture," along with top notch firms still debuting on everyone markets, only in minimized amounts, according to PitchBook.